- Work +1 202 508 4600
Mark S. Popofsky, a veteran of the landmark Microsoft trial, chairs Ropes & Gray’s Antitrust Practice Group. A first-chair trial lawyer, Mark litigates antitrust, intellectual property and other complex business litigation matters. Mark’s litigation practice includes jury trials, class actions (including cartel cases), arbitrations and appeals throughout the federal and states courts. Mark regularly counsels Fortune 500 companies on the full-range of antitrust matters across numerous industries, including high technology, telecommunications, medical device, pharmaceuticals, aerospace, manufacturing, health care and consumer products. With deep and recognized experience in the intersection of intellectual property and antitrust, Mark advises leading Internet, semiconductor, hardware, software and telecommunications clients on business practices, competitor collaborations and distribution arrangements. He also represents parties in civil and criminal antitrust investigations and transactions before the U.S. Department of Justice and the Federal Trade Commission. https://www.ropesgray.com/biographies/p/mark-s-popofsky.aspx?AK=pop#sthash.CLMbxoe0.dpuf
United States: Antitrust
Civil litigation/class actions
Within: Civil litigation/class actions
Ropes & Gray LLP differentiates itself by its ability to handle both defendant and plaintiff work and acts for companies such as Google, Cablevision and Polar Air Cargo. The firm’s broad-ranging expertise in class actions complements its antitrust practice, as demonstrated by the fact that the team, which is led by Washington DC-based Mark Popofsky, is involved in high-profile cases such as Re Optical Disk Drive Products Antitrust Litigation, where Popofsky and Boston-based Jane Willis are defending Hitachi-LG Data Services. Healthcare is a real sector strength and a cross-office team of Washington DC and San Francisco lawyers represented Questcor Pharmaceuticals (now part of Mallinckrodt Pharmaceuticals) in a challenge brought by Retrophin to Questcor’s acquisition of the rights to Novartis’ Synacthen drug. Jerome Katz is a key contact in New York.